Treatment of Tuberculosis Flashcards
Why is mycobacterium tuberculosis difficult to treat?
- multiples slowly
- survives in protected intracellular location (i.e. macrophage)
- propensity to develop resistance to antimicrobial agents
- therapy can last up to two years so issues with patient compliance
- issues of drug toxicity and interactions (especially relavent with HIV patients)
Describe first-line therapy for M. tuberculosis and M. avium complex
M. tuberculosis: RIPES - rifampin* (RIF), isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), streptomycin
M. avium complex: clarithormycin + ethambutol (or clofazimine or ciprofloxacin or amikacin)
* In HIV patients, use of rifabutin can decrease teh drug interactions with PIs and NNRTIs
Describe Rifabutin and Rifapentine vs. Rifampin
Rifabutin and Rifapentine are derivatives of Rifampin
- Rifabutin is a less potent inducer of CYP450 than is Rifampin
- Rifapentine has a longer half-life than Rifampin or Rifabutin so that it may be given on a once-weekly schedule
How do you treat latent TB infection?
Recent evidence shows that 3 month treatment with Isoniazid (INH) and Rifapentine (RPT) with Directly Observed Therapy is effective in preventing TB and is more frequently completed than the US standard of 9 months of INH without DOT.
Who is INH-RPT not recommended for?
- Children <2 y/o
- HIV+ recieving antiretroviral treatmetn
- Pregnant women or women expecting to become pregnant
- Patients with latent TB infection with presumed INH or RIF resistance
Can combination of Rifampin and Pyrazinamide be offered for treatmetn of latent TB?
NO d/t reports of severe liver injury and deaths
What is the basic TB disease regimen for ACTIVE cases of TB?
Initial Phase (8 weeks): INH, RIF, PZA, EMB
- Note: EMB can be discontinued if drug susceptibility studies demonstrate susceptibility to first-line drugs
Continuation Phase (18 weeks): Daily INH and RIF or Twice-weekly INH and RIF
- Once weekly INH/RIF can be used for HIV- patietns without cavities on CXR and who have negative AFB at completion of inital phase
Isoniazid MOA
- Interferes with mycolic acid synthesis (i.e. disrupts cell wall synthesis)
- Bacteriocidal for rapidly dividng bacilli, such as those found in extracellular cavitary lesions
- Bacteriostatic agaisnt organisms found within closed caseous lesions and macrophages that divide slowly and intermittently.
- Penetrates host cells - **effective for intracellular bacilli **
Isoniazid Resistance
- Inability to take up the drug
- Alteration in the target enzyme
- Overproduction of the target enzyme
- Do NOT use as a single agent in ACTIVE TB cases as resistant organisms rapidly emerge
Isoniazid Pharmacology
Absorption: rapidly absorbed from GI tract with oral dose; can be administered IM
Distribution: all tissues and fluids; penetrates inflamed meninges and achieves therapeutic levels in CSF. Crosses placenta and is distributed into breast milk.
Metabolism: metabolized in liver to inactive metabolites, primarily with acetylation via N-acetyl transferase.
- slow vs. fast acetylators affects therapy (plasma concentrations can be 2-3X lower in fast acetylators)
- chronic liver disease will decrease metabolism, so dose must be lowered
Excretion: drug and inactive metabolites excreted in urine
Isoniazid Adverse Effects
PERIPHERAL NEUROPATHY
- Burning or prickling sensation in hands & feet
- Competition between isoniazid and pyridoxal phosphate: corrected with vitamin B6 (pyridoxine) supplementation and is more frequent in malnourished, diabetics and alcoholics
DOSE RELATED HEPATOTOXICITY: the major toxic recation is hepatitis d/t toxic metabolite from acetylation of isoniazid
Allergic rxns non-dose related
Isoniazid Drug Interactions
- Antacids with Al3+ salts decrease absorption (administer 1h before any antacids)
- Corticosteroids decrease effiacy: prednisone reduces plasma [INH] and INH inhibits the hepatic metabolism of cortisol.
- Inhibits P450 isozyme that metabolizes phenytoin, diazepam, fluxetine, nelfinavir, etc
Rifampin MOA, Resistance, and Spectrum
Include Rifampin, Rifabutin, and Rifapentine
MOA: Bactericidal; inhibits DNA dependent RNA polymerase by binding to the beta subunit of the Mb RNA polymerase
Resistance
- Alteration in beta subunit of the RNA polymerase so that it not longer binds drug
- Never given as a single agent becuase resistance emerges rapidly
Spectrum: intra- or extracellular mycobacteria
Rifampin Pharmacology
Absorption: well absorbed from oral administation; impaired by food or para-aminosalicylic acid
Distribution: penetrates all tissues well, including CSF; 75-85% protein bound
Metabolism: deacetylated in liver
Excretion: primarily in bile (30% unchanged) and smal amount via renal tubular secretion. *No adjustment needed for renal insufficiency. *
Rifampin Adverse Effects
- Discolors body fluids (tears, urine, saliva) orange-red
- GI distrubances and nervous system complaints
- Fever, chills and aches
- Hepatotoxicity - more relavent in patients that are slow acetylators; jaundice occurs with chronic liver disease, alcoholics and elderly